Centocor (Johnson & Johnson) awarded the largest patent verdict in U.S. history

In Insights, Uncategorized

6 July, 2009

1.67 billion U.S. dollars, $1.16 billion in lost profit, and $504 million in royalties. That’s what Centocor is awarded in damages for infringement of their patents.

On Monday, June 29, a jury found that Abbott Laboratories had willfully infringed two patents covering antibodies against tumor necrosis factor owned by Centocor. Abbott’s drug Humira was found to infringe Centocor’s U.S. Patent Nos. 7,070,775 and 7,276,239. Humira is widely used in the treatment of various forms of arthritis, and is also approved for psoriasis and Crohn’s Disease.

Humira has been somewhat of a blockbuster for Abbott, and is said to have generated $4.5 billion in global sales last year. Centocor has made it clear that it isn’t seeking to block sales of the drug, only to get a share of the profit.

Therefore, this verdict is in a way the ultimate evidence that the patent system actually works in practice: it gives a patent owner a time-limited exclusive right to prevent others from commercially exploiting the protected invention. And needless to say, a strong patent portfolio can have a significant value. Ask Centocor.

Inga-Lill Andersson, European Patent Attorney

You may also be interested in:

The Business of IP – Understanding and Creating Value: Part 6 – Costs of IP

In this six-part series, Anders Isaksson explores some of the critical factors and motivators for why companies, small or

Read more...

IP Pitfalls When Creating a New Product Line (Or a New Company) – Part 2: Patents, Designs and IP Contract Considerations

When creating a new product line or starting a new company, many types of considerations and preparations are necessary.

Read more...

IP Pitfalls When Creating a New Product Line (Or a New Company) – Part 1: Trademarks and Domains

When creating a new product line or starting a new company, many types of considerations and preparations are necessary.

Read more...

Mobile Sliding Menu